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Rates of glaucomatous visual field change
before and after transscleral
cyclophotocoagulation: a retrospective case
series
Dominik Bleisch*, Sandra Furrer and Jens Funk
Abstract
Background: The primary goal of glaucoma treatment is to lower and control intraocular pressure (IOP) and
thereby prevent functional deterioration. For glaucomas that are refractory to medical and incisional surgical
therapies, transscleral diode cyclophotocoagulation (TCP) is a well-established procedure to effectively decrease IOP.
This study investigated rates of visual field (VF) change in patients with glaucoma before and after TCP.
Methods: This retrospective case series investigated rates of VF changes in glaucoma patients before and after they
underwent TCP. At least four VF examinations were required, two before and two after surgery. VF examinations
were performed using standard automated perimetry and rates of change were calculated by linear regression
analysis of mean deviation (MD) values measured over time.
Results: A total of 46 eyes of 43 patients were included and followed on average 3.6 years before and 2.1 years after TCP.
67 % of the eyes showed further progression of glaucoma following surgery. Mean preoperative MD change was
−0.21 dB/year (SE = 0.08, 95 % CI [−0.06, −0.37]). Postoperatively the mean change was −0.26 dB/year (SE = 0.22 95 % CI
[0.38, −0.48]) which results in a difference between pre- and postoperative MD rate of 0.05 dB/year (p = 0.824). The mean
MD value was worse after surgery and dropped by 1.73 dB (SE = 0.58, 95 % CI [−0.59, −2.87], p = 0.003). Intraocular
pressure (IOP) decreased from 23.2 mmHg (SD = 4.67) before TCP to 14.3 mmHg (SD = 3.17) after TCP (p < 0.001). For
each 1 mmHg of IOP reduction after surgery, postoperative rate of VF loss decreased by 0.15 dB/year.
Conclusion: Rates of glaucomatous visual field loss did not significantly change after TCP and the majority of the eyes
showed further progression of glaucoma after surgery. Mean MD value was considerably lower after TCP.
Keywords: Glaucoma, progression, rate of progression, visual field, transscleral cyclophotocoagulation
Background
Increased IOP has been identified as a major risk factor
in the development and progression of glaucoma [1, 2].
Large prospective trials demonstrated the beneficial ef-
fect of reduced levels of IOP in delaying VF deterior-
ation [3–5]. The primary goal of glaucoma treatment is
therefore to effectively lower and control IOP and
thereby prevent functional deterioration. This can either
be achieved with medical therapy, incisional surgery or
cyclodestructive methods such as TCP. For glaucomas
that are refractory to medical and incisional surgical
therapies, TCP is a well-established procedure and the
effectiveness of the treatment on IOP reduction has been
shown in various studies [6–10]. However, the final goal
of glaucoma treatment remains the prevention of further
VF deterioration as one of the most important factors
for visual disability in patients with glaucoma. Unfortu-
nately several investigations have shown that VF defects
continue to progress in the majority of patients in rou-
tine clinical glaucoma care [11–14]. Obviously, the com-
mon treatment modalities are not able to completely
halt VF progression, yet they play an important role in
slowing it down. A number of studies have provided
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data on the changes in the VF after trabeculectomy
[2, 15, 16]. However, data on VF changes after TCP
has, to our knowledge, previously not been published.
The purpose of the current study is to compare the
rates of change in the VF before and after TCP in pa-
tients with difficult to manage glaucoma.
Methods
Subjects and data selection
This study retrospectively investigated the medical his-
tory of all glaucoma patients who underwent TCP at the
University Hospital Zurich, Switzerland, between January
2007 and December 2012 (n = 388). The investigation
was approved by the Regional Ethics Committee Zurich
and conducted adhering to the tenets of the Declaration
of Helsinki and in compliance with all local and national
regulations and directives. Indications for TCP included
uncontrolled glaucoma despite maximum tolerated med-
ical treatment, drug allergy / intolerance, non-adherence
to medication regimens or lack of response to filtration
surgery. Patients were selected if two or more reliable
VF examinations were available before and after TCP, ei-
ther at our hospital or at the patients’ private ophthal-
mologist. All perimetric tests were performed with the
Octopus G1/G2 program with dynamic strategy. VFs
with test results showing more than 15 % false positive
answers were excluded. Other exclusion criteria were fil-
tration surgery or cataract extraction during follow-up,
congenital glaucoma and other ophthalmic co-morbidity
(except cataract) with serious impact on VFs. Patients
with very low vision whose visual acuity was only classi-
fied with the semiquantitative scale "counting fingers",
"hand motion", "light perception", and "no light percep-
tion" were excluded from the study. In order to analyse
a trend in VF change the negative “Mean defect index”
of every VF including the date of the examination was
extracted from the Octopus printout. The MD change
over time was calculated in decibel (dB) per year. Rates
of VF changes were computed for the total sample of 46
eyes, for phakic and pseudophakic eyes separately and
for each of the two glaucoma types “primary open-angle
glaucoma (POAG)” and “pseudoexfoliation glaucoma
(PEXG)” separately.
In order to quantify the effect of TCP on IOP we com-
pared IOP measurements before and after surgery. Base-
line IOP was defined as the mean of all IOP
measurements performed within one month before the
surgery. Postoperative IOP was determined as the mean of
the last 3 measurements of the follow-up. If less than
three IOP measurements were available, only two (11
eyes) or one (9 eyes) IOP value was taken into account.
For seven eyes no postoperative IOP value was available
and they were therefore excluded from the IOP analysis.
Both baseline IOP and postoperative IOP were calculated
from IOP values without any changes in the ocular
hypotensive medications, and all measurements were per-
formed using Goldmann applanation tonometry. Accord-
ing to the Guidelines on Design and Reporting of
Glaucoma Surgical Trials [17] we defined treatment suc-
cess as mean postoperative IOP between 4 and 20 mmHg,
provided that medical hypotensive therapy was not
increased.
As secondary endpoints, we analysed changes in
medical hypotensive therapy and best-corrected visual
acuity (BCVA). Before TCP, medical therapy was de-
fined as the number of antiglaucoma medications
used prior to surgery. Postoperatively, the number of
medications was recorded at the last follow-up visit.
If fixed combination medications were used, the num-
ber of active ingredients was documented. Altogether,
medical therapy was obtained for a subgroup of 38
eyes. Preoperative BCVA was recorded from the last
visit prior to surgery and postoperative BCVA was
documented at the end of the follow-up. BCVA was
analysed for a subgroup of 33 eyes.
Other data collected from the medical history and re-
ported in this paper included gender, age, eye left or
right, type of glaucoma, glaucoma surgery before follow-
up, number and dates of all TCPs and lens status.
Statistical methods
Data were recorded in Excel and analysed with SPSS
Statistics Version 22 (IBM SPSS, Chicago, IL, USA). At
patient level, descriptive statistics such as mean, stand-
ard deviation, minimum and maximum were computed
for continuous variables, whereas absolute and relative
frequencies were computed for discrete variables. Asso-
ciations between age, gender and number of operations
were analysed by Spearman rank correlation.
Association between MD and follow-up time corrected
for pre- and postoperative, and interaction between
postoperative follow-up time and pre-/postoperative sta-
tus were computed. In order to account for imbalances
in the number of VF per eye a linear mixed model was
used [18]. The slope of the change in MD over time, to-
gether with a 95 % confidence interval for slope, were
read up from the SPSS output. The MD change for each
eye before and after TCP was calculated and displayed
in a scatterplot. In addition, possible confounders such
as gender and age were included in the analysis.
Mean values of IOP, medical hypotensive therapy and
BCVA before and after TCP were compared using a
paired t-test.
In order to investigate the influence of factors which
are potentially associated with postoperative rates of VF
changes, we performed a number of linear regression
analysis with “MD at study start”, “preoperative MD
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change”, “IOP reduction”, “postoperative IOP” and “pre-
operative BCVA” as independent variables.
Results of statistical analysis with p-values smaller than
0.05 were considered to be statistically significant. Data
more than 10 years before TCP was not eligible.
Results
Out of 388 patient records, we obtained data from 43
patients (46 eyes) with a total of 421 VF examinations.
Mean patient age at the time of TCP was 67.7 years with
a range from 12 to 88 years. Mean preoperative follow-
up time was 3.6 years, postoperatively patients were
followed for 2.1 years on average. Table 1 shows detailed
demographic data and other baseline characteristics.
After TCP, average IOP in the analysed subgroup of 39
eyes was reduced by 8.9 mmHg (p< 0.001, SD = 4.47),
which corresponds to a relative reduction of 38 %. IOP
reduction for each eye is illustrated in the scatterplot in
Fig. 1. Success rate of the treatment, as defined earlier,
was 82 % (31 of 38 eyes). Six eyes only achieved an
IOP ≤ 20 mmHg with an increase of medical hypotensive
therapy and in one eye IOP could not successfully be
controlled.
Glaucoma types included in the study are displayed in
Table 2. VF defects at the time of intervention covered
the whole spectrum of disease severity with a mean MD
of −9.6 dB (median 7.8; SD 6.8) and a range from
−23.2 dB to +2.8 dB.
The mean rate of VF loss before TCP was −0.21 dB/
year (SE = 0.08, 95 % CI [−0.06, −0.37]). After TCP the
mean progression rate was −0.26 dB/year (SE = 0.22,
95 % CI [0.38, −0.48]) which results in a difference be-
tween pre- and postoperative MD change of 0.05 dB/
year (p = 0.8235). The mean MD value dropped by
1.73 dB (SE = 0.58, 95 % CI [−0.59, −2.87], p= 0.00293)
after TCP (Fig. 2). Adjusted for the variables age, gender
and eye left/right, MD rate before TCP was −0.21 dB/
year (SE = 0.10, 95 % CI [−0.01, −0.41]), after TCP
Table 1 Demographics and baseline characteristics
Mean (No) SD Median Min Max
Age (years) 67.7 14.1 68.8 12 88
Gender Female (%) 23 (50)
Eye right (%) 27 (59)
Treatment per eye 1.2 0.5 1 1 3
No. of preoperative VFs 5.5 3.3 5 2 14
No. of postoperative VFs 3.6 1.7 3 2 8
Last preop VF to surgery (days) 243.4 303.0 128 7 1421
Surgery to first postop VF (days) 273.2 138.6 269 16 596
Retreatment (%) 20
Follow-up preoperative (years) 3.6 2.8 3 0.2 9.9
Follow-up postoperative (years) 2.1 1.4 1.7 0.4 5.8
IOP preoperative 23.2 4.7 23 14.4 33.2
IOP postoperative 14.3 3.2 14.1 8 22
No. of AGM preop. 3 1.5 3 0 6
No. of AGM postop. 2.44 1.42 3 0 6
BCVA preoperative 0.16 0.56 0.1 2.9 0
BCVA postoperative 0.22 0.52 0.15 2.9 −0.1
Phakic at the time of surgery (%) 23 (50)
Surgical treatment before FU (%) 37 (80)
– Trabeculectomy (%) 18 (39)
– ELT (%) 4 (9)
– SLT (%) 3 (6)
– ALT (%) 4 (9)
– Tube shunt (%) 2 (4)
– Deep sclerectomy (%) 5 (11)
– YAG–laser iridotomy (%) 1 (2)
IOP, intraocular pressure in mmHg; AGM, antiglaucoma medications; BCVA, best–corrected visual acuity in logMAR; FU, follow–up; Preop, preoperative; Postop,
postoperative; ELT, Excimer laser trabeculoplasty; SLT, Selective laser trabeculoplasty; ALT, Argon laser trabeculoplasty
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−0.32 dB/year (SE = 0.20, 95 % CI [0.28, −0.49]) and the
mean MD value dropped by 1.61 dB (SE = 0.52, 95 % CI
[−0.59, −2.63], p = 0.00210). Rates of VF change for
POAG, PEXG and phakic/pseudophakic eyes are listed
in Table 3.
Possible confounders were analysed and their individ-
ual effect on the VF loss was calculated. Neither age nor
gender had a significant effect on the results.
The results of the linear regression analysis for the fac-
tors potentially associated with postoperative rates of VF
changes are shown in Table 4. Larger IOP reduction was
associated with significantly (p= 0.04) slower postopera-
tive VF loss. For each 1 mmHg of IOP reduction after
surgery, postoperative rate of VF loss decreased by
0.15 dB/year. For the variables MD change preoperative,
BCVA preoperative and IOP postoperative, no signifi-
cant correlation was found.
Progression rates on the eye level are illustrated with a
scatterplot in Fig. 3. 31 of 46 eyes (67 %) showed further
progression of glaucoma after surgery. Among them,
nine eyes showed a deceleration in VF loss whereas 22
eyes progressed on a faster rate following laser treat-
ment. Only a minority of 15 eyes improved after TCP.
The analysis with a Spearman rank correlation showed
no significant (ρ = 0.148, p = 0.326) association between
pre- and postoperative MD rate.
Discussion
The main goal of glaucoma treatment is to effectively
lower and control IOP and prevent further deterioration
of the VF. Data from the Advanced Glaucoma Interven-
tion Study showed that low IOP is associated with re-
duced progression of VF defects, supporting evidence
from earlier studies of a protective role of low IOP in VF
deterioration [4]. The 38 % relative IOP reduction found
in this study is in accordance with numerous other stud-
ies demonstrating the effectiveness of TCP in signifi-
cantly reducing IOP [6–10]. Our investigation on the
rates of glaucomatous VF change before and after TCP
showed, during a mean preoperative follow-up time of
3.6 years, an MD rate of −0.21 dB/year (SE = 0.08, 95 %
CI [−0.06, −0.37]). This VF loss is in agreement with a
Fig. 1 Average IOP in mmHg before and after TCP. Each dot represents an eye. Dots below the diagonal correspond to a decrease in IOP
after surgery
Table 2 Types of glaucoma included in the study
Glaucoma type No %
POAG 24 52
PEXG 12 26
Secondary glaucoma after trauma 2 5
Aphakic glaucoma 4 9
CACG 2 4.5
Other 2 4.5
POAG, primary open-angle glaucoma; PEXG, pseudoexfoliation glaucoma;
CACG, chronic angle-closure glaucoma
Bleisch et al. BMC Ophthalmology  (2015) 15:179 Page 4 of 7
study from Chauhan et al. [12] that reported a median
MD rate of −0.05 (interquartile range 0.13, −0.3) in pa-
tients under routine glaucoma care. After TCP the rate of
VF loss increased by 0.05 dB/year (p = 0.8235) to an MD
rate of −0.26 dB/year (SE = 0.22 95 % CI [0.38, −0.48])
over a mean postoperative follow-up time of 2.1 years. We
found that larger IOP reduction was associated with a sig-
nificant (p = 0.04) decrease in postoperative rate of VF
loss. For each 1 mmHg of IOP reduction after surgery,
postoperative rate of VF loss decreased by 0.15 dB/year.
Despite good IOP lowering and a significant association
between IOP reduction and postoperative progression
rates, our study showed that TCP could not halt glau-
comatous VF progression in our group of patients and in
the majority of the eyes (67 %), VF loss continued after
surgery. Even though it was not significant, this change is
in contradiction with previous studies which reported im-
proved MD rates after glaucoma filtration surgery with a
comparable relative IOP reduction [15, 16]. Folgar et al.
[16] found that mean global progression rates significantly
decreased from −1.48 dB/year (SD 1.4) before surgery to
−0.43 dB/year (SD 0.8) after surgery. Each 1 mmHg of
IOP reduction after trabeculectomy resulted in a 0.1 dB/
year decrease in the global rate of progression. Bertrand et
al. [15] found an average difference between the rates of
MD loss of 0.20 dB/year (p = 0.15).
The significant drop in mean MD value after TCP is
striking. The loss of visual acuity after TCP is a common
complication and could explain deteriorations in the VF
[7, 10]. Since we only documented a post-operative
BCVA loss of 0.06 logMAR, loss of visual acuity can
hardly be responsible for the damage in the VF. The
lower number of VF examinations after TCP (3.6 after
vs. 5.5 before TCP) could be another source of error. Be-
sides the quality of each examination, the validity of MD
values strongly depends on the number of VF tests per-
formed. Chauhan et al. [19] showed that a total MD
change of −2 dB over a 3 year period requires 4 annual
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Table 3 Rates of visual field progression per type of glaucoma
and lens status
Before TCP (SE) After TCP (SE) Δ p
MDC POAG −0.08 (0.07) −0.09 (0.28) 0.01 0.966
MDC PEXG −0.39 (0.06) −0.81 (0.30) 0.42 0.164
MDC phakic −0.10 (0.00) −0.45 (0.26) 0.35 0.180
MDC pseudophakic −0.28 (0.06) 0.03 (0.22) 0.31 0.168
MDC, mean deviation change in dB/year; SE, standard error; Δ, difference;
POAG, primary open-angle glaucoma; PEXG, pseudoexfoliation glaucoma
Table 4 Linear regression analysis of factors associated with
postoperative rates of VF changes
R2 β Slope p
MD at study start 0.0360 −0.1904 0.000 0.205
MD change preoperative 0.0007 0.0279 0.007 0.854
IOP reduction 0.1095 −0.3309 −0.150 0.040
IOP postoperative 0.0113 −0.1065 −0.120 0.519
BCVA preoperative 0.0010 −0.0330 −0.000 0.844
MD, mean deviation in dB; IOP, intraocular pressure in mmHg; BCVA, best-
corrected visual acuity in logMAR
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examinations in order to detect the change with 80 %
power. Although VF examinations where performed by
many different private ophthalmologists, testing condi-
tions before and after TCP were identical for each pa-
tient since they remained at the same private practice
during the entire time they were followed. Examination
quality was ensured by excluding VF examinations with
more than 15 % false positive answers.
Cataract might have played a role in the postoperative
worsening of the VF since we found that phakic eyes
progressed considerably faster after TCP than pseudo-
phakic eyes (−0.45 dB/y versus 0.03 dB/y). Even though
this difference was not statistically significant, it indi-
cates that lens opacification probably contributed to the
lack of reduction in VF loss after surgery.
Our relatively large proportion of PEXG could be an-
other reason for the VF loss after TCP. We found that
MD loss after surgery increased substantially among pa-
tients with PEXG compared to almost no increase
among POAG patients (0.42 dB/y versus 0.01 dB/y).
Earlier studies suggested that pseudoexfoliation is a
strong factor for progression of glaucoma and it is pos-
sible that natural progression of the disease is respon-
sible for the increased MD loss [3, 20].
The main limitation of our study is its retrospective
nature. Since our hospital is a referral centre and many
patients return to their private ophthalmologists after
surgical treatment, data has not only been collected at
our hospital but was obtained from several referring
ophthalmologists. Our findings should therefore be
interpreted with caution.
Conclusion
Our study shows that rates of glaucomatous VF loss did
not significantly change after TCP. Despite a successful
IOP lowering, the majority of the eyes showed further
progression of glaucoma after surgery. To our know-
ledge, this study is the first published investigation on
the rate of VF change before and after TCP and adds
further insights in the progression of VF defects after in-
vasive IOP lowering. It remains unclear why rates of
glaucomatous VF progression after TCP were not re-
duced and whether the postoperative lower baseline MD
value results from treatment or from the natural pro-
gression of glaucoma.
Abbreviations
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Fig. 3 MD rate in dB/year for each eye before and after TCP. Dots above the diagonal correspond to a slowing of VF loss after TCP whereas dots
below refer to an accelerated VF loss after surgery
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